First North-listed Cyxone recently published its Q1 report, a period during which the company carried out a rights issue of 61 MSEK, and advanced the company's drug candidates rabeximod and T20K. In April, Cyxone announced that the company will prioritise the rheumatoid arthritis programme with Rabeximod, expecting to initiate a phase IIb study later this year. BioStock reached out to CEO Tara Heitner for a comment.

Read the interview with Cyxone's CEO Tara Heitner at biostock.se:

https://www.biostock.se/en/2022/05/cyxone-focuses-on-the-ra-programme/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

https://news.cision.com/cyxone/r/biostock--cyxone-focuses-on-the-ra-programme,c3570866

(c) 2022 Cision. All rights reserved., source Press Releases - English